In preclinical models of lipopolysaccharide (LPS)-induced endotoxemia, pre-treatment with KUF-13046 reduced serum levels of IL-1β and IL-18 by over 60%, correlating with improved survival rates. Researchers are now using it to dissect the timing of inflammasome activation during septic shock.
For labs incorporating KUF-13046 into their workflow, specific attention must be paid to protocol optimization: KUF-13046
To understand the value of KUF-13046, it is helpful to compare it to existing research tools: Expected outcomes: faster searches
| Compound | Selectivity | Bioavailability | Primary Issue | | :--- | :--- | :--- | :--- | | Propionate (natural ligand) | Low | Poor | Off-target effects, rapid metabolism | | TUG-1374 | Moderate | Moderate | Stability issues in plasma | | KUF-13046 | High | High (78% oral F) | Pending Phase I trials | fewer support tickets
KUF-13046 outperforms natural ligands by resisting rapid hepatic clearance, and it surpasses older synthetic agonists by achieving true pathway bias.
A concise rollout plan to adopt better identifier management:
Expected outcomes: faster searches, fewer support tickets, clearer documentation, improved compliance.
In preclinical models of lipopolysaccharide (LPS)-induced endotoxemia, pre-treatment with KUF-13046 reduced serum levels of IL-1β and IL-18 by over 60%, correlating with improved survival rates. Researchers are now using it to dissect the timing of inflammasome activation during septic shock.
For labs incorporating KUF-13046 into their workflow, specific attention must be paid to protocol optimization:
To understand the value of KUF-13046, it is helpful to compare it to existing research tools:
| Compound | Selectivity | Bioavailability | Primary Issue | | :--- | :--- | :--- | :--- | | Propionate (natural ligand) | Low | Poor | Off-target effects, rapid metabolism | | TUG-1374 | Moderate | Moderate | Stability issues in plasma | | KUF-13046 | High | High (78% oral F) | Pending Phase I trials |
KUF-13046 outperforms natural ligands by resisting rapid hepatic clearance, and it surpasses older synthetic agonists by achieving true pathway bias.
A concise rollout plan to adopt better identifier management:
Expected outcomes: faster searches, fewer support tickets, clearer documentation, improved compliance.